当前位置: 首页 > 期刊 > 《中外医学研究》 > 201416
编号:13677729
不同剂量利妥昔单抗治疗慢性免疫性血小板减少症的临床疗效观察(2)
http://www.100md.com 2014年6月5日 雷晓宇 罗自勉 娄典等
第1页

    参见附件。

     参考文献

    [1] British Committee for Standards in Haematology General Haematology Task Force.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults,children and in pregnancy[J].Br J Haematol, 2003, 120(4): 574-596.

    [2] Zaja F, Marin L, Chiozzotto M, et al. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab[J]. Am J Hematol, 2012, 87(3): 321-323.

    [3]侯明.成人特发性血小板减少性紫癜诊断治疗专家共识[J].中华血液学杂志, 2009, 30(9): 647-648.

    [4] Bertrand G, Raphael P, Olivier F, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study[J]. Blood, 2008, 112(5): 999-1004.

    [5] Vrushali D, Amr H, Philip K, et al.Can rituximab replace splenectomy in immune thrombocytopenic purpura[J].Indian J Hematol Blood Transfus, 2009, 25(1): 6-9.

    [6] Zaja F, Vianelli N, Volpetti S, et al.Low-dose rituximab in adult patients with primary immune thrombocytopenia[J].Eur J Haematol, 2010, 85(4): 329-334.

    (收稿日期:2014-02-06) (编辑:黄新珍)

    

您现在查看是摘要介绍页,详见PDF附件